Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11497885 | 0.78 | ALDH1A1 (0.58) | ALDH1A1TDP1TSHRCA2NPC1 | |
| SCHEMBL11437771 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TDP1TSHRCA2NPC1 | |
| SCHEMBL10577277 | 0.76 | CHRNB2 (0.34) | ALDH1A1TDP1TSHRPTPN1CA2 | |
| SCHEMBL11802171 | 0.76 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHRCA2NPC1 | |
| SCHEMBL29684449 | 0.75 | CA2 (0.68) | ALDH1A1TDP1TSHRPTPN1CA2 | |
| SCHEMBL9249193 | 0.75 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRCA2NPC1 | |
| SCHEMBL8733283 | 0.75 | ALDH1A1 (0.65) | ALDH1A1TDP1TSHRCA2NPC1 | |
| Ethylene SCHEMBL28844160 | 0.75 | ALDH1A1 (0.90) | ALDH1A1TDP1TSHRCA2NPC1 | |
| SCHEMBL9594148 | 0.74 | HTT (0.33) | ALDH1A1TDP1TSHRPTPN1ABCB1 | |
| SCHEMBL9594550 | 0.74 | ALDH1A1 (0.32) | ALDH1A1TDP1TSHRPTPN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4228266-A | FROM CYCLOPENTADIENE, DICYCLOPENTADIENE, ALKYL-SUBSTITUTED COMPOUNDS THEREOF AND A HYDROXYSTYRENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-10-14 | — | — | US | claimed |
| US-4129557-A | CYCLOPENTADIENE, DICYCLOPENTADIENE, HYDROXYSTYRENE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1978-12-12 | — | — | US | claimed |
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| EP-1954696-B1 | 2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-1954696-B1 | 2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-7645778-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645778-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1954696-A2 | 2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | Bristol-Myers Squibb Company (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2006078621-A9 | 2-PHENOXY-N- (1, 3 , 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2006078621-A9 | 2-PHENOXY-N- (1, 3 , 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20060173002-A1 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-03 | — | — | US | disclosed |
| WO-2006078621-A2 | 2-PHENOXY-N- (1, 3 , 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-27 | — | — | WO | disclosed |
| EP-0069069-B1 | POLYMERISABLE COMPOSITIONS AND POLYMERISATION PRODUCTS RESULTING THEREFROM | CIBA-GEIGY AG (CH) | 1988-03-02 | — | — | EP | disclosed |
| US-4228266-A | FROM CYCLOPENTADIENE, DICYCLOPENTADIENE, ALKYL-SUBSTITUTED COMPOUNDS THEREOF AND A HYDROXYSTYRENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-10-14 | — | — | US | disclosed |
| US-4129557-A | CYCLOPENTADIENE, DICYCLOPENTADIENE, HYDROXYSTYRENE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1978-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | P2RY1, P2RY11, P2RY2 | ALDH1A1 2158/4885TDP1 1299/4885TSHR 1272/4885 |
| US-20060173002-A1 | Heteroaryl compounds as P2Y1 receptor inhibitors | P2RY1, P2RY11, P2RY2 | ALDH1A1 2158/4885TDP1 1299/4885TSHR 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.